{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T04:11:36Z","timestamp":1794802296853,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1208\/s12248-019-0335-9","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T15:02:43Z","timestamp":1559314963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Skin Delivery and Irritation Potential of Phenmetrazine as a Candidate Transdermal Formulation for Repurposed Indications"],"prefix":"10.1208","volume":"21","author":[{"given":"Ying","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin S.","family":"Murnane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonalika A.","family":"Bhattaccharjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Blough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Banga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,31]]},"reference":[{"issue":"6","key":"335_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/2045125312458311","volume":"2","author":"M Isaac","year":"2012","unstructured":"Isaac M, Holvey C. Transdermal patches: the emerging mode of drug delivery system in psychiatry. Ther Adv Psychopharmacol. 2012;2(6):255\u201363.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"SUPPL. 1","key":"335_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.drugalcdep.2006.01.015","volume":"83","author":"S McColl","year":"2006","unstructured":"McColl S, Sellers EM. Research design strategies to evaluate the impact of formulations on abuse liability. Drug Alcohol Depend. 2006;83(SUPPL. 1):52\u201362.","journal-title":"Drug Alcohol Depend"},{"issue":"17","key":"335_CR3","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.2174\/156802606778249766","volume":"6","author":"R Rothman","year":"2006","unstructured":"Rothman R, Baumann M. Therapeutic potential of monoamine transporter substrates. Curr Top Med Chem. 2006;6(17):1845\u201359.","journal-title":"Curr Top Med Chem"},{"key":"335_CR4","unstructured":"Malenka RC, Nestler EJ, Hyman SE. Higher cognitive function and behavioral control. In: Sydor A, Brown RY, editors. Molecular neuropharmacology: A foundation for clinical neuroscience, 2nd ed. New York: McGraw-Hill Medical; 2009. p. 318.\u00a0"},{"issue":"2","key":"335_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1001\/jama.1957.02980200015005","volume":"165","author":"C Ressler","year":"1957","unstructured":"Ressler C. Treatment of obesity with phenmetrazine hydrochloride, a new anorexiant. J Am Med Assoc. 1957;165(2):135\u20138.","journal-title":"J Am Med Assoc"},{"issue":"7095","key":"335_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S0140-6736(59)90562-8","volume":"2","author":"J Evans","year":"1959","unstructured":"Evans J. Psychosis and addiction to phenmetrazine (preludin). Lancet. 1959;2(7095):152\u20135.","journal-title":"Lancet."},{"issue":"1","key":"335_CR7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1124\/jpet.108.143701","volume":"329","author":"SS Negus","year":"2009","unstructured":"Negus SS, Baumann MH, Rothman RB, Mello NK, Blough BE. Selective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine. J Pharmacol Exp Ther. 2009;329(1):272\u201381.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"335_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1177\/0269881113482532","volume":"27","author":"DJ Heal","year":"2013","unstructured":"Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present - a pharmacological and clinical perspective. J Psychopharmacol. 2013;27(6):479\u201396.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"335_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/00325481.2016.1120642","volume":"128","author":"M Gasior","year":"2016","unstructured":"Gasior M, Bond M, Malamut R. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations. Postgrad Med. 2016;128(1):85\u201396.","journal-title":"Postgrad Med"},{"issue":"3","key":"335_CR10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/ADM.0000000000000206","volume":"10","author":"BL Bolin","year":"2016","unstructured":"Bolin BL, Stoops WW, Sites JP, Rush CR. Abuse potential of oral phendimetrazine in cocaine-dependent individuals: implications for agonist-like replacement therapy. J Addict Med. 2016;10(3):156\u201365.","journal-title":"J Addict Med"},{"issue":"1-2","key":"335_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijpharm.2018.08.033","volume":"550","author":"Sindhu S. Ganti","year":"2018","unstructured":"Ganti SS, Bhattaccharjee SA, Murnane KS, Blough BE, Banga AK. Formulation and evaluation of 4-benzylpiperidine drug-in-adhesive matrix type transdermal patch. Int J Pharm. 2018;550(1\u20132):71-8.\u00a0","journal-title":"International Journal of Pharmaceutics"},{"issue":"1","key":"335_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0378-5173(97)00430-4","volume":"165","author":"S Gao","year":"1998","unstructured":"Gao S, Singh J. Effect of oleic acid\/ethanol and oleic acid\/propylene glycol on the in vitro percutaneous absorption of 5-fluorouracil and tamoxifen and the macroscopic barrier property of porcine epidermis. Int J Pharm. 1998;165(1):45\u201355.","journal-title":"Int J Pharm"},{"issue":"1-2","key":"335_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ijpharm.2017.06.041","volume":"528","author":"Ashana Puri","year":"2017","unstructured":"Puri A, Murnane KS, Blough BE, Banga AK. Effects of chemical and physical enhancement techniques on transdermal delivery of 3-fluoroamphetamine hydrochloride. Int J Pharm. 2017;528(1-2):452-62.\u00a0","journal-title":"International Journal of Pharmaceutics"},{"issue":"5","key":"335_CR14","first-page":"330","volume":"58","author":"G Yener","year":"2003","unstructured":"Yener G, G\u00f6n\u00fcll\u00fc \u00dc, \u00dcner M, De\u01e7im T, Araman A. Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of celecoxib through human skin. Pharmazie. 2003;58(5):330\u20133.","journal-title":"Pharmazie."},{"issue":"5","key":"335_CR15","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1023\/A:1015314314796","volume":"19","author":"AP Funke","year":"2002","unstructured":"Funke AP, Schiller R, Motzkus HW, Ginther C, Miller RH, Lipp R. Transdermal delivery of highly lipophilic drugs: in vitro fluxes of antiestrogens, permeation enhancers, and solvents from liquid formulations. Pharm Res. 2002;19(5):661\u20138.","journal-title":"Pharm Res"},{"issue":"2","key":"335_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0939-6411(01)00158-8","volume":"52","author":"E Larrucea","year":"2001","unstructured":"Larrucea E, Arellano A, Santoyo S, Ygartua P. Combined effect of oleic acid and propylene glycol on the percutaneous penetration of tenoxicam and its retention in the skin. Eur J Pharm Biopharm. 2001;52(2):113\u20139.","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"335_CR17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/toxsci\/48.2.218","volume":"48","author":"M Perkins","year":"1999","unstructured":"Perkins M, Osborne R, Rana FR, Ghassemi A, Robinson MK. Comparison of in vitro and in vivo human skin responses to consumer products and ingredients with a range of irritancy potential. Toxicol Sci. 1999;48(2):218\u201329.","journal-title":"Toxicol Sci"},{"key":"335_CR18","unstructured":"Test No. 439: In vitro skin irritation - reconstructed human epidermis test method. OECD; 2013. (OECD Guidelines for the testing of chemicals, section 4)."},{"issue":"3","key":"335_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5487\/TR.2017.33.3.191","volume":"33","author":"M Lee","year":"2017","unstructured":"Lee M, Hwang JH, Lim KM. Alternatives to in vivo Draize rabbit eye and skin irritation tests with a focus on 3D reconstructed human cornea-like epithelium and epidermis models. Toxicol Res. 2017;33(3):191\u2013203.","journal-title":"Toxicol Res"},{"issue":"3","key":"335_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.tiv.2003.10.004","volume":"18","author":"DJ Davies","year":"2004","unstructured":"Davies DJ, Ward RJ, Heylings JR. Multi-species assessment of electrical resistance as a skin integrity marker for in vitro percutaneous absorption studies. Toxicol in Vitro. 2004;18(3):351\u20138.","journal-title":"Toxicol in Vitro"},{"key":"335_CR21","unstructured":"In vitro EpiDerm\u2122 skin irritation test (EPI-200-SIT) for use with MatTek corporation\u2019s reconstructed human epidermal model EpiDerm \u2122 (EPI-200-SIT). 2017."},{"key":"335_CR22","unstructured":"FDA. Inactive Ingredient Search for Approved Drug Products Inactive Ingredient Search for Approved Drug Products Page 2 of 2. 2013;5\u20136."},{"issue":"3","key":"335_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0939-6411(98)00030-7","volume":"46","author":"E Squillante","year":"1998","unstructured":"Squillante E, Needham T, Maniar A, Kislalioglu S, Zia H. Codiffusion of propylene glycol and dimethyl isosorbide in hairless mouse skin. Eur J Pharm Biopharm. 1998;46(3):265\u201371.","journal-title":"Eur J Pharm Biopharm"},{"key":"335_CR24","unstructured":"ChemAxon. Chemicalize - instant cheminformatics solutions [Internet]. Chemicalize. 2018 [cited 2018 Sep 30]. Available from: \n                    https:\/\/chemicalize.com\/#\/calculation"},{"issue":"8","key":"335_CR25","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40265-015-0392-z","volume":"75","author":"R Altman","year":"2015","unstructured":"Altman R, Bosch B, Brune K, Patrignani P, Young C. Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology. Drugs. 2015;75(8):859\u201377.","journal-title":"Drugs."},{"issue":"4","key":"335_CR26","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1124\/pr.117.014803","volume":"70","author":"TD M\u00fcller","year":"2018","unstructured":"M\u00fcller TD, Clemmensen C, Finan B, DiMarchi RD, Tsch\u00f6p MH. Anti-obesity therapy: from rainbow pills to polyagonists. Pharmacol Rev. 2018;70(4):712\u201346.","journal-title":"Pharmacol Rev"},{"issue":"SUPPL","key":"335_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.addr.2012.09.032","volume":"64","author":"AC Williams","year":"2012","unstructured":"Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2012;64(SUPPL):128\u201337.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1-3","key":"335_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0378-5173(86)90057-8","volume":"33","author":"Bruce J. Aungst","year":"1986","unstructured":"Aungst BJ, J. Rogers N, Shefter E. Enhancement of naloxone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxides and amides. Int J Pharm. 1986;33(1\u20133):225\u2013234.","journal-title":"International Journal of Pharmaceutics"},{"issue":"3","key":"335_CR29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1023\/A:1015921702258","volume":"6","author":"BJ Aungst","year":"1989","unstructured":"Aungst BJ. Structure\/effect studies of fatty acid isomers as skin penetration enhancers and skin irritants. Pharm Res. 1989;6(3):244\u20137.","journal-title":"Pharm Res"},{"issue":"1","key":"335_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11095-009-9985-0","volume":"27","author":"SA Ibrahim","year":"2010","unstructured":"Ibrahim SA, Li SK. Efficiency of fatty acids as chemical penetration enhancers: mechanisms and structure enhancement relationship. Pharm Res. 2010;27(1):115\u201325.","journal-title":"Pharm Res"},{"key":"335_CR31","unstructured":"Osborne JL, Nelson M, Enscore DJ, Yum SI, Gale RM, inventors; Alza Corporation, assignee. Subsaturated nicotine transdermal therapeutic system. United States patent US 6165497A. 2000 Dec 26.\u00a0"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-019-0335-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-019-0335-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-019-0335-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T23:06:53Z","timestamp":1590793613000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-019-0335-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,31]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["335"],"URL":"https:\/\/doi.org\/10.1208\/s12248-019-0335-9","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,31]]},"assertion":[{"value":"28 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"70"}}